PBYIライブシグナル | Getagraph.comで利益を最大化

買う 107769 min ago

@ $7.35

発行日: 15 2月 2024 @ 05:31

リターン: -31.29%

前回のシグナル: 2月 14 - 05:35

前回のシグナル: 売る

リターン: 18.17 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:37):

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally...

Stats
本日の出来高	89 108.00
平均出来高	583 904
時価総額	243.45M
EPS	$0 ( 2024-02-29 )
次の収益日	( $-0.160 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	11.22
ATR14	$0.0120 (0.24%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Auerbach Alan H	Buy	6 577	Common Stock
2024-03-15	Auerbach Alan H	Buy	9 047	Stock Option (Right to Buy)
2024-02-12	Wong Alvin F	Buy	43 307	Common Stock
2024-02-12	Wong Alvin F	Buy	59 946	Stock Option (Right to Buy)
2024-02-12	Nougues Maximo F	Buy	43 307	Common Stock

INSIDER POWER
69.66
Last 99 transactions
Buy: 2 879 886 \| Sell: 561 464

ボリューム相関

長: 0.04 (neutral)

短: 0.91 (very strong)

Signal:(63.361) Expect same movement, but be aware

Puma Biotechnology Inc 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Puma Biotechnology Inc 相関 - 通貨/商品

0.18
( neutral )

0.22
( neutral )

0.00
( neutral )

0.31
( neutral )

0.53
( weak )

0.12
( neutral )

Puma Biotechnology Inc 財務諸表

Annual	2023
収益:	$235.64M
総利益:	$172.96M (73.40 %)
EPS:	$0.460

FY	2023
収益:	$235.64M
総利益:	$172.96M (73.40 %)
EPS:	$0.460

FY	2022
収益:	$228.00M
総利益:	$172.90M (75.83 %)
EPS:	$0.0204

FY	2021
収益:	$253.16M
総利益:	$189.45M (74.84 %)
EPS:	$-0.720

Financial Reports:

No articles found.

Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

リアルタイムの更新： Puma Biotechnology Inc [PBYI]

Upcoming Earnings Alert